VOLITION: The power of choice after virological suppression
People living with HIV naive to treatment valued being empowered with the option to switch to VOCABRIA + REKAMBYS soon after achieving virologic suppression with daily oral DTG/3TC[1]
In the VOLITION study, people naive to treatment started with daily oral DTG/3TC. Participants who were virologically suppressed*, between Week 4 and Week 16, were then given the choice to either continue with daily oral DTG/3TC or switch to 2-monthly VOCABRIA + REKAMBYS.[1]
What participants chose
In the VOLITION study, people living with HIV naive to treatment valued being empowered with the option to switch soon after achieving virologic suppression: [1]
How people living with HIV felt
“How does it feel to be given a choice about your future HIV treatment?” (n=155)†
I am happy to know there are options for future treatment to match my lifestyle
It provides me with an option to suit my needs and daily life
It gives me hope for the future
Have you discussed VOCABRIA + REKAMBYS with your eligible patients?
Learn about the impact of shared decision making
Learn more about why people living with HIV may prefer VOCABRIA + REKAMBYS to daily oral therapy
Empowering people living with HIV naive to ART the opportunity to switch to VOCABRIA + REKAMBYS soon after achieving virologic suppression with DTG/3TC allowed participants to choose a treatment option that met their individualised needs, which could be a key component to treatment success and quality of life.[1]
VOLITION co-primary study endpoints: Median time to virologic suppression (HIV-1 RNA <50 copies/mL) from baseline with DTG/3TC was 4.1 (95% CI: 4.1, 4.3) weeks. The proportion of participants receiving VOCABRIA + REKAMBYS with HIV-1 RNA <50 copies/mL per Snapshot algorithm at Month 11 results are not yet reported.[1]
*HIV-1 RNA <50 copies/mL; ~16-week suppression phase.[1]
†Includes all participants who reported that they were given the choice to switch from DTG/3TC to every-2-month VOCABRIA
+ REKAMBYS. Participants could select more than one response. The three most commonly reported responses are provided.[1]
Prescribing Information and Adverse Event Reporting for DOVATO (dolutegravir/lamivudine) is available here.
ART=antiretroviral therapy; CI=confidence interval; DTG/3TC=dolutegravir/lamivudine; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; RNA=ribonucleic acid.
References:
- Felizarta F, Gutner C, Jonsson-Oldenbüttel C, et al. The Power of Choice: Strong Preference for CAB+RPV LA Following Rapid Suppression With DTG/3TC in Newly Diagnosed People Living With HIV. Presented at: The 13th International AIDS Society (IAS) Conference; July 13–17, 2025; Kigali, Rwanda. Poster EP0170.
REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.
PM-GB-CBR-WCNT-250009 | March 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
